ImaginAb Secures $12,500,000 Series A Funding Round

  • Feed Type
  • Date
    3/28/2012
  • Company Name
    ImaginAb
  • Mailing Address
    Undisclosed Los Angeles, CA 90049
  • Company Description
    ImaginAb’s mission is to transform the clinical management of cancer and autoimmune diseases via targeted molecular imaging. We re-engineer therapeutic antibodies against biologically important targets into small proteins optimized for diagnostic imaging with Positron Emission Tomography (PET). We believe that in the era of targeted molecular therapy, there is a major unmet need for true companion in vivo diagnostics to help realize the promise of personalized medicine.
  • Website
    http://www.imaginab.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $12,500,000
  • Transaction Round
    Series A
  • Proceeds Purposes
    It says the funds will be used to speed clinical development of its cancer and immunology imaging programs, which are focused on the staging of metastatic prostate and pancreatic cancer.
  • M&A Terms
  • Venture Investor
    Novartis Venture Fund
  • Venture Investor
    Undisclosed

By posting a comment, you agree to our terms and conditions.